Source-grounded facts extracted from VYCOR MEDICAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
VYCOR MEDICAL INC reported the three months ended March 31, 2026 results: revenue $458,540.
“the traditional blade retractor group, implying safer tumor resection using VBAS. Financial Results For the three months ended March 31, 2026, the Company reported revenue of $458,540, an increase of $22,162 (or 5%) over the 2025 period. The Vycor Medical division (VBAS) generated revenue of $440,441, an increase of $21,921 (or 5%) over the 2025 period. Most of”
VYCOR MEDICAL INC reported financial results for the year ended December 31, 2025.
“On March 31, 2026, we issued a press release regarding our financial results for the year ended December 31, 2025.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.